Acute Myeloid Leukemia Pipeline Drugs Assessment

Veröffentlicht von: pbi
Veröffentlicht am: 28.03.2018 08:32
Rubrik: Umwelt & Energie


(Presseportal openBroadcast) - Acute Myeloid Leukemia Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Pressekontakt:

Acute Myeloid Leukemia Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Acute Myeloid Leukemia Pipeline Drugs Assessment

Overview:
Acute myeloid leukemia is a type of blood cancer,affects white blood cells. It enables progress rapidly, requires immediate treatment. Acute myeloid leukemia symptoms develop over a few weeks and become increasingly more severe. Symptoms may include tiredness, pale skin, breathlessness and unusual & frequent bleeding.
If symptoms are persisted, diagnostic tests may include blood tests, bone marrow test, lumbar puncture and sometimes genomic testing may be suggested. There is no specific cure available for acute myeloid leukemia. But it is treated by the combination of therapies that include chemotherapeutic agents, stem cell transplantation, radiation therapy and targeted therapy.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/acute-myeloid-leukemia-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:
Acute myeloid leukemia pipeline drugs are segmented based onroute of administration, trial phase,and company
By Route of Administration, acute myeloid leukemia pipeline drugs are segmented into
• Oral
• Parenteral
• Others
By Trial Phase, Acute Myeloid Leukemia pipeline drugs are segmented into
• Pre-clinical phase
• Phase-I
• Phase II
• Phase-III
By Company, Acute Myeloid Leukemia pipeline drugs are segmented into
• Cyclacel Pharmaceuticals Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Novartis AG (Switzerland)
• H. BoehringerSohn AG &Ko. KG (Germany)

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/acute-myeloid-leukemia-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu


Space Analysis:
Many of the drugs and treatments are being developed under the clinical trials for the treatment of acute myeloid leukemia. Companies are looking for the most effective chemotherapy drugs while still avoiding the side effects. Some of the chemotherapeutics drugs under clinical trials include sapacitabine, tipifarnib,andbortezomib. Furthermore, immunotherapies and stem cell therapies also effectively studying by the researchers to treat the acute myeloid leukemia. In addition, targeted therapy class of drugs such as FLT3 Inhibitors, Histone deacetylase inhibitors,and aurora kinase inhibitors are the promising for the treatment of acute leukemia.
• In October 2017, U.S. Food and Drug Administration granted fast-track designation for development of gilteritinib for adult patients with FLT3 mutation positive relapsed or refractory acute myeloid leukemia.

Report Description:
Acute Myeloid Leukemia Pipeline Drugs Assessment report studies the various therapeutics under clinical development for uterine fibroids treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the uterine fibroids pipeline drugsdevelopment. This report studies the dynamics of the Acute Myeloid Leukemia Pipeline Drugs i.e. drivers, challenges,andopportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on uterine fibroids pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/acute-myeloid-leukemia-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis of each drug candidates in the clinical trial phases

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/acute-myeloid-leukemia-pipeline-drugs-assessment/
About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com

Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.